Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01970501 · ClinicalTrials.gov registry record · Phase 2
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
A Phase 2 study, sponsored by ARCA Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
NCT01970501: Completed Phase 2 study, sponsored by ARCA Biopharma.
NCT01970501 is a Phase 2 study that has completed, run by ARCA Biopharma. The registered enrollment target is 267 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (101% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01970501, a Phase 2 study, has completed, sponsored by ARCA Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
Study Summary
This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.
Primary Outcome
Time-to-event is calculated as the date of the event minus the date of initiation of efficacy follow-up, with 1 added in order to include both the start date and end date of the interval. Cox's proportional hazards model will be used to calculate estimated hazard ratios and 95% confidence intervals. The calculations will be performed with the SAS PHREG procedure, with the stratification variables specified in the STRATA statement and the treatment group comparator and any covariates being examin
Interventions
- DRUG metoprolol succinate
- OTHER Placebo oral capsule
- DRUG bucindolol hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-12-28 |
| Phase | Phase 2 |
What the finished NCT01970501 record still lists
NCT01970501 is an interventional study that assigns participants to a tested intervention. The registered 267 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (101% higher).
The record links to 0 conditions, and to 3 interventions - of which metoprolol succinate is the first listed.
NCT01970501 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01970501 about?
NCT01970501 is a clinical study titled "Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure". This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.
What is the current status of trial NCT01970501?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2014-04. Estimated completion is 2017-12-28.
What interventions are being tested in trial NCT01970501?
The interventions under investigation include: metoprolol succinate (DRUG), Placebo oral capsule (OTHER), bucindolol hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01970501?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01970501's enrollment target sits among peer trials
267 209th of 2000 higher than 1,792 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04997109 · 267 participants · NA
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
- NCT05355701 · 267 participants · Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- NCT06203509 · 267 participants · NA
Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia